Study to gather information on the safety and how radium-223 dichloride, an alpha particle-emitting radioactive agent, works under routine clinical practice in Taiwan in patients with castration-resistant prostate cancer (CRPC) which has spread to the bone (RAPIT)
In this observational study researchers want to gather more information about safety and survival in patients suffering from castration-resistant prostate cancer (CRPC) which has spread to the bone and were treated with radium-223 in routine clinical practice in Taiwan. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
- Histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate with bone metastases - Treatment decision for Radium-223 according to local label needs to be made independent from and before patient enrollment in the study by the investigator - No contra-indications according to the local marketing authorization
- Previously treated with Radium-223 for any reason - Currently treated in clinical trials including other Radium-223 studies or planned participation in an investigational program with interventions outside of routine clinical practice during the study period
Many locations, Taiwan, China
E-mail: [email protected]
Phone: (+)1-888-84 22937
Safety and Effectiveness of Xofigo® (Radium-223 dichloride) in Routine Clinical Practice Settings in Taiwan